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Objective. Patients with multiple sclerosis (MS) are often suffering from neuropathic pain. Antiepileptic drugs (AEDs) and tricyclic
antidepressants (TCAs) are commonly used and are susceptible to be involved in drug interactions. The aim of this retrospective
study was to investigate the prevalence of use of antiepileptic and antidepressive drugs in MS patients and to discuss the theoretical
potential for interactions.Methods. Review of the medical records from all patients treated at a dedicated MS rehabilitation centre
in Norway between 2009 and 2012. Results. In total 1090 patients attended a rehabilitation stay during the study period. Of these,
342 (31%; 249 females) with mean age of 53 (±10) years and EDSS 4.8 (±1.7) used at least one AED (gabapentin 12.7%, pregabalin
7.7%, clonazepam 7.8%, and carbamazepine 2.6%) or amitriptyline (9.7%). Polypharmacy was widespread (mean 5.4 drugs) with
60% using additional CNS-active drugs with a propensity to be involved in interactions. Age, gender, and EDSS scores did not differ
significantly between those using and not using AED/amitriptyline.Conclusion. One-third ofMS patients attending a rehabilitation
stay receive AED/amitriptyline treatment. The high prevalence of polypharmacy and use of CNS-active drugs calls for awareness
of especially pharmacodynamic interactions and possible excessive adverse effects.
1. Introduction
Neuropathic pain affects the quality of life and a recent meta-
analysis of pain in MS reported a pooled prevalence of 63%,
with estimates ranging from 29% to 86% [1, 2]. Treatment of
neuropathic pain is associated with adverse reactions, espe-
cially long-term treatment where tolerance and dependence
issues are concerned. Antiepileptic drugs (AEDs) such as
carbamazepine, gabapentin, and pregabalin and the tricyclic
antidepressant (TCA) amitriptyline are recommended and
frequently used in the management of neuropathic pain [3–
5]. AEDs are among themost susceptible drugs to be involved
in pharmacokinetic as well as pharmacodynamic interactions
[6]. Patients with MS often use several types of CNS-active
drugs; yet little research has been done to highlight potential
polypharmacy issues. There are no prevalence studies that
estimate the extent of use of AEDs in patients with MS.
In Norway, the MS prevalence is about 203 per 100,000
[7]. Epilepsy has a prevalence of 0.7–1% worldwide [8]. There
is an increased risk of developing epilepsy related to other
neurological diseases as MS, and a prevalence of epilepsy and
MS of 2.2% has been estimated [9]. During a 40-year follow-
up of patients with MS in Norway, the risk of having active
epilepsy was increased fourfold [10].The use of AEDs to treat
epilepsy in patients with MS is therefore also a treatment
concern. Depression is one of the most common mental
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disorders, and, in the US, the prevalence is estimated to
be 8.3% of lived years with disability [11]. Recently, it was
shown that 10.7% of patients with MS (𝑛 = 75) were taking
antidepressants [12].
The aim of this retrospective study was to investigate the
prevalence of use of antiepileptic and antidepressive drugs in
MS patients at a referral center and furthermore to discuss
the theoretical potential for interactions, which may have a
large impact on the pharmacological treatment of patients
with MS.
2. Material and Methods
2.1. Study Population. This retrospective prevalence study
was performed at the MS Rehabilitation Centre in Hakadal,
Norway, to investigate the pharmacological treatment of
patients admitted to the centre, based on data from the
medical records.The centre is part of theNorwegian specialist
healthcare service and patients are referred by their doctor to
the centre for a four-week rehabilitation stay. Although any
patient may be referred to the centre, more patients living
in the southern, eastern, and northern health regions are
referred as these regions have written agreements with the
centre. The main intake criteria at the centre are the need
for specialized interdisciplinary rehabilitation and potential
for improvement during the stay. All patients are examined
by a liaison neurologist fromAkershus University Hospital at
the beginning and end of their stay. All medical records from
examinations of patients at the end of their stay in the period
01.01.2009–31.12.2012 were reviewed. Information on patients
treatedwith at least oneAEDor amitriptylinewas collected to
investigate the suspected polypharmacy issues and potential
for pharmacokinetic and pharmacodynamic interactions.
2.2. Inclusion Criteria. The study inclusion criteria were MS-
diagnosis and use of at least one AED or amitriptyline, the
only antidepressant with an indication for neuropathic pain
in Norway. AEDs were defined as any drug with ATC code
N03A (AnatomicalTherapeutic Chemical classification) [16].
Some patients had more than one stay at the centre during
the inclusion period. In those cases the most recent stay was
chosen and previous stays were disregarded.
2.3. Data Handling and Analyses. Data for the patient group
as awholewere considered, no interventionswere performed,
and follow-up data for the individual patients were not avail-
able. For every included patient, the following was registered:
age, gender, Expanded Disability Status Scale (EDSS) score,
and all current medications including dosages. Comorbid
diagnoses such as bipolar disorder, depression, epilepsy, and
migraine were also registered among patients using an AED
or amitriptyline. To investigate and discuss the theoretical
potential for drug interactions, AEDs and amitriptyline were
categorized as Group I drugs, and other concomitantly used
CNS-active drugs were categorized as Group II drugs. For
Group I drugs the indication was collected. Group II drugs
were considered especially relevant for potential interactions
(mostly pharmacodynamic) with AEDs and amitriptyline. To
study the use of those drugs in more detail, they were divided
based on their mechanism of action: 𝛼
2
-blockers, GABAB
agonists, benzodiazepines, opioids, selective serotonin reup-
take inhibitors (SSRI), and selective noradrenaline reuptake
inhibitors (SNRI). Potential groups containing less than five
patients were disregarded. This was done with the intention
to increase awareness of the possible clinical consequences in
practice and will be discussed.
If the medical record included an EDSS score, the EDSS
score together with the patient’s gender and age was collected,
even if the patient failed to meet the inclusion criteria. This
was done to provide a means to characterize the total patient
population with an EDSS profile.
All patient data was stored anonymously in the database.
The study was approved by the local ethics committee.
Statistical analyses included Fischer’s 𝑡-test for binomial
distributions, Mann-Whitney test for comparing nonpara-
metric data (EDSS scores), and Student’s 𝑡-test when compar-
ing normally distributed data. A significance level of 𝑝 < 0.05
was chosen.
3. Results
3.1. Study Population. A total of 1090MS patients underwent
a rehabilitation stay during the study period. Table 1 shows
patients’ characteristics in detail.
Twenty (1.8%) of the patients had a diagnosis of epilepsy.
Less than five of the patients using amitriptyline or any other
tricyclic antidepressant had a stated diagnosis of depression
in their medical records.
3.2. Use of Antiepileptic Drugs and Antidepressants. The use
of AEDs, amitriptyline, and other CNS-active drugs is shown
in Table 2. In total 342 (31%; 249 females) patients with
mean age of 53 (±10) years and EDSS 4.8 (±1.7; 𝑛 = 196)
used at least one AED (295; 27%) or amitriptyline (106;
10%). There were 89 (26%) patients who used more than
one AED or amitriptyline. Age, gender, and EDSS scores did
not differ significantly between those using and not using
AED/amitriptyline.
Dosage variability was extensive (Table 2) and varied
between 18-fold for gabapentin, 12-fold for pregabalin and
clonazepam, and 4.5-fold for carbamazepine.
In addition to the above-mentioned AEDs primarily used
in neuropathic pain, seven other AEDs were used to treat
epilepsy and other conditions (mood disorders including
bipolar disorder, migraine, and pain), as shown in Table 2. No
TCA other than amitriptyline was used for treatment of pain.
Twenty-nine percent of the patients using AEDs and/or
amitriptyline were 60 years and above (𝑁 = 100). The
average gabapentin dosage for these patients was 19% lower
than for younger patients, 1277 (±687) and 1578 (±799) mg,
respectively (𝑝 < 0.05). A similar tendency was seen with
pregabalin, although nonsignificant.
3.3. Polypharmacy Aspects and Drug Interactions. On aver-
age, patients receiving AED and/or amitriptyline treatment
were using a total of 5.4 (range 1–19) different prescription
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Table 1: Patients’ characteristics.
Study population Description
Number of patients (𝑁 = 1090) AED/amitriptyline: 342 (31%; 249 females)
Gender distribution Mean age 53 (±10) years
Age distribution Patients 60 years and above (29%;𝑁 = 100)
Range 21–73 years
EDSS score MS Rehabilitation Centre population: mean 4.8 (±1.8,𝑁 = 585)AED/amitriptyline: mean 4.8 (±1.7;𝑁 = 196)
Polypharmacy
AED/amitriptyline: 5.4 (range 1–19) different prescription drugs
203 (59%) used 5 or more drugs
24 (7%) used 10 drugs or more
Comorbid disorders, epilepsy MS Rehabilitation Centre population:𝑁 = 20 (1.8%), diagnosis of epilepsy
Mood disorder AED/amitriptyline:𝑁 = 71 (21% used either 𝛼
2
-blocker, SNRI or SSRI)
Use of disease-modifying drugs
AED/amitriptyline:𝑁 = 130 (38%)
Natalizumab:𝑁 = 40 (12%)
Glatiramer acetate:𝑁 = 37 (11%)
Interferon-beta:𝑁 = 36 (11%)
Mitoxantrone:𝑁 = 7 (2%)
Fingolimod:𝑁 = 6 (2%)
Ocrelizumab:𝑁 = 1 (0.3%)
drugs; 203 (59%) used 5 or more drugs and 24 (7%) used 10
drugs or more (Figure 1).
The AEDs and amitriptyline (Group I) were mostly used
to treat neuropathic pain. The potential of drug interactions
for other concomitantly used CNS-active drugs (Group II)
was reviewed. Among the patients using one ormore drugs in
Group I, 204 (60%) also used one or more drugs in Group II.
Drugs often used to treat mood disorders (𝛼
2
-blockers, SSRI
and SNRI) were used by 71 (21%) of the patients using drugs
in Group I.
Thirty-eight percent of the patients using AEDs/ami-
triptyline (𝑁 = 130) were also receiving disease-modifying
treatment (Table 1).
Figure 2 shows the wide distribution of functional levels
in the MS Rehabilitation Centre population divided into two
groups based on the use of AED/amitriptyline.
4. Discussion
In this study we demonstrate a wide use of AEDs and
amitriptyline in a large population of patients with MS.
Furthermore, the extent of polypharmacy in this patient
population was high and 60% used additional CNS-active
drugs. This forms the basis to discuss and evaluate the
theoretical possibilities for interactions that may have a large
impact on the treatment of the individual patient and calls for
careful monitoring.
4.1. Study Population. The results in the present study reflect
clinical use of AEDs and amitriptyline to treat pain in MS
in a large population comprising about 10% of the patients
withMS inNorway [7].The female-to-male ratio and average
age of the study population were comparable to the whole
Norwegian MS population (2.4 versus 2.2 and 53 versus 51
years, resp.) [7]. The number of patients with an epilepsy
diagnosis in this MS population of 1.8% was closer to the
general population than previously reported [9].
4.2. Use of Antiepileptic Drugs and Amitriptyline. The present
results show that the use of AEDs and amitriptyline was
extensive in patients across all functional levels.The wide use
of gabapentin, pregabalin, and amitriptyline for the treatment
of pain in patients with MS is in line with international
recommendations [3, 4]. Gabapentin and pregabalin have
equal pharmacodynamic actions and are predominantly uti-
lized in treatment of neuropathic pain, rather than epilepsy
in Norway [5, 13]. We have recently shown that the phar-
macokinetic variability of both pregabalin and gabapentin
in clinical practice is more than 100-fold [17]. Head-to-
head comparisons of the two are lacking, and even though
pregabalin is considerablymore expensive, the cost-efficiency
is similar [18]. Clonazepam is often used to treat spasms and
may be given in a small dose in addition to other drugs to
treat pain. The enzyme inducer carbamazepine is still the
AED of choice in trigeminus neuralgia, although skin rash
is a common side effect andmajor reason for discontinuation
[19]. Carbamazepine was frequently used in patients withMS
and epilepsy, which calls for attention in combination with
other drugs metabolized in the liver. Other AEDs are used
only rarely in the treatment of pain [5].
There were large differences in dosages described for
pregabalin, gabapentin, and clonazepam. For gabapentin,
the pharmacokinetic absorption process is variable between
patients and intraindividually due to limited absorption
capacity [20], which explains why some patients will need a
higher dose to reach a therapeutic serum concentration. Age
also contributes to pharmacokinetic variability. Patients 60
years and above generally have lower renal clearance andmay
therefore require lower dosages of drugs cleared renally, such
as gabapentin and pregabalin, to avoid adverse reactions. Age
4 Multiple Sclerosis International
Table 2: AEDs and amitriptyline in pain and other indications 2009–2012 (𝑁 = 342) and potential drug interactions.
Drug 𝑁 (%) Averagedosage (mg)
Range
(mg) Indication
Route of
elimination
Propensity to
interact
Possible
pharmacodynamic
interactions
Group I: antiepileptic drugs (AEDs) (acting by inhibiting voltage gated sodium or calcium channels or as GABAergic drugs) or
amitriptyline (TCA) (inhibiting reuptake of serotonin and noradrenaline∗∗)
Gabapentin
(AED) 138 (40.3) 1491 300–3600
Epilepsy (2)
Pain or spasms∗ (136) Renal Very low
Excessive
CNS-sedation
involving sedation,
dizziness, fatigue,
cognitive
impairment, and so
forth within GroupI
or in combination
with GroupII
Clonazepam
(AED) 85 (24.9) 1 0.25–3
Epilepsy (1)
Pain or spasms∗ (84)
Hepatic
CYP3A4
Moderate
Metabolism
inducible
Pregabalin
(AED) 24.6 (7.7) 448 50–900
Epilepsy (1)
Pain or spasms∗ (83) Renal Very low
Carbamazepine
(AED) 28 (8.2) 469 200–900
Epilepsy (6)
Bipolar disorder (1)
Pain or spasms∗ (21)
Hepatic
CYP3A4
Substantial
Induces
CYP3A4/2C9/1A2
Lamotrigine
(AED) 14 (4.1) 157 75–300
Epilepsy (6)
Bipolar disorder (3)
Pain or spasms∗ (5)
Hepatic
UGT1A4
UGT2B7
Substantial
Valproate
(AED) 8 (2.3) 1012 600–1500
Epilepsy (5)
Bipolar disorder (1)
Pain or spasms∗ (1)
Hepatic
CYP2C9/19/
2A6/B6 oxidases
Substantial
Levetiracetam
(AED) 5 (1.5) 1200 500–2000
Epilepsy (3)
Pain or spasms∗ (2) Esterases in blood Very low
Oxcarbazepine
(AED) 3 (0.9) 1080 600–1440
Epilepsy (1)
Pain or spasms∗ (2)
Hepatic
Arylketone
reductase
Moderate
Phenytoin
(AED) 2 (0.6) 150 100–200 Epilepsy (2)
Hepatic CYP2C9/
2C19 Substantial
Topiramate
(AED) 1 (0.3) 100 NA Epilepsy (1)
Hepatic
CYP isoenzymes Substantial
Phenobarbital
(AED) 1 (0.3) 45 NA Epilepsy (1)
Hepatic
CYP2C9/
2C19/E1
Moderate
Amitriptyline
(TCA) 106 (31.0) 29 5–75 Pain or spasms
∗ (106)
Hepatic
CYP2D6
2C19
3A4
Moderate
Metabolism may
be induced/
inhibited
Group II: Pharmacodynamic interactions
GABAB agonist
Opioids
Benzodiazepines
(GABAA agonist)
SSRI/SNRI
𝛼
2
-blockers
85 (24.9)
76 (22.2)
66 (19.9)
64 (18.7)
11 (3.2)
60% used at least one Group II drug in combination with a Group I drug, giving
rise to a potential for drug interactions, where pharmacodynamic interactions are
of most clinical relevance based on the data presented above. All drug classes result
in a reduction in CNS-excitation based on their mechanisms of actions.
Pharmacokinetic interactions are of limited importance quantitatively, since the
AEDs most commonly used here have a low propensity to interact with
pharmacokinetic processes
Excessive
CNS-sedation
involving sedation,
dizziness, fatigue,
cognitive
impairment, and so
forth within
GroupII or in
combination with
GroupI
∗Pain/spasms were reported in the medical records or assumed when no other indications or comorbidities were reported.
∗∗Antagonism at other receptors causing adverse effects; histaminergic, noradrenergic, and muscarinergic receptors.
The data are based on [6, 13–15]. TCA: tricyclic antidepressant; AED: antiepileptic drug; VGCC: voltage gated calcium channels; VGSC: voltage gated sodium
channels.
had probably been taken into account in these patients, since
the dosages of both drugs were approximately 20% lower in
patients 60 years and above than in younger patients.
Altogether 11 different AEDs were used by patients with
MS, and in many cases this reflects comorbidity and possibly
also off-label use of lamotrigine, valproic acid, and oxcar-
bazepine, since these drugs do not have a license indication
for pain in Norway. These drugs have shown clinical efficacy
in neuropathic pain and are approved for this indication in
other countries [13].
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Figure 1: Drug count distribution among patients receiving
antiepileptic and/or tricyclic antidepressant drugs (𝑁 = 342).
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Figure 2: Expanded Disability Status Scale score distribution of
the MS Rehabilitation Centre population (𝑁 = 585) divided into
two groups based on the use of antiepileptic drugs (AED) and/or
amitriptyline (TCA).
4.3. Polypharmacy Aspects. We have shown that polyphar-
macy was widespread in this patient population. Although
AEDs are well known to be involved in pharmacokinetic
interactions, this is not of particular concern for MS
patients since they mainly used newer AEDs (pregabalin and
gabapentin) with less propensity to interact than the older
enzyme inducers and inhibitors [6, 14]. Pharmacodynamic
interactions are of greater concern since half of the patients
used an opioid, a benzodiazepine or baclofen (GABAB
agonist) in addition to their AED/amitriptyline therapy.
Patients using an AED and/or amitriptyline used 5.4
drugs on average, which is regarded as a considerable drug
load, and altogether up to 19 concomitant drugs were listed
in one patient. The association between polypharmacy (≥5
drugs) and adverse drug reactions is well known and calls for
attention and closemonitoring [21].The clinical consequence
of a specific drug interactionmay be difficult to predict in the
individual patient. Different aspects of the pharmacological
treatment may be affected, such as the drug efficacy or the
adverse reaction profile. All drugs listed among the Group
I and Group II drugs can cause sedation and general CNS
depression. Considering that fatigue is one of the most com-
mon MS symptoms affecting approximately 75% of patients
[22, 23], these pharmacodynamic interactions are likely to be
clinically relevant.
4.4. Clinical Considerations. In a study of 142MS patients
in Norway with a pain prevalence of 65%, only one-third
were receiving treatment [24]. Our finding that one-third
of the MS patients at the MS Rehabilitation Centre receive
AED/amitriptyline treatment, across all functional levels and
ages, adds to this.
Rational combination of several CNS-active drugs with
extensive pharmacological variability requires careful consid-
eration of clinical as well as basic pharmacological aspects of
pharmacotherapy. Treatment strategies in MS are changing,
and the clinical experience regarding efficacy and tolerability
of newly introduced drugs is limited [25]. A reduction in total
drug load will probably result in less adverse reactions caused
by pharmacodynamic interactions in polypharmacy patients,
possibly improving quality of life [26].
The dosages should be reduced when several CNS-active
drugs are given concomitantly to avoid excessive adverse
reactions such as sedation, dizziness, and cognitive impair-
ment. This is of special importance in patients 60 years
and above due to extensive pharmacokinetic variability and
increased sensitivity to CNS-active drugs. For example, pre-
gabalin combined with zopiclone or opioids increases the
risk of pharmacodynamic interaction and sedation, as well
as other CNS-depressant effects, which have been reported
in WHO’s VigiBase in relation to abuse, tolerance, and
dependence [27, 28].
The implementation of therapeutic drug monitoring
(TDM) may contribute to an optimization of drug therapy
in the individual patient by serum concentration measure-
ments. TDM is used as a tool for tailoring the treatment with
AEDs in epilepsy, aswell as other indications, due to extensive
pharmacokinetic variability between patients, challenges to
handle drug interactions, and problems with adherence and
for quality assurance of the treatment [29, 30].
The MS Rehabilitation Centre in Hakadal is a rehabilita-
tion centre and, therefore, the most disabled and the oldest
patients with MS are not included in the study population.
To assess the selection bias we compared the study pop-
ulation’s demographic data and EDSS scores with regional
MS populations. We found that the study population has
a similar functional level as the general MS population in
one Norwegian county [31]. Peaks at scores 4.0 and 6.5 as
seen in Figure 2 are typical for cross-sectional studies of MS
populations, reflecting slower disease progression at these
functional levels [31].
4.5. Methodological Considerations. Limitations of the study
include the fact that the medical records may be incomplete.
Thus, neither disease duration nor diagnosis of neuropathic
pain was systematically reviewed, and a prevalence of neu-
ropathic pain or its relationship with disease duration could
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not be estimated. Neuropathic pain was assumed as indi-
cation for the use of an AED/amitriptyline when no other
indication was mentioned, based on the given indications in
the summary of product characteristics and on the extensive
use of gabapentin and pregabalin in neuropathic pain in
Norway [5].The records were, however, suitable to gain infor-
mation on ongoing pharmacological treatment. The dosages
recorded were assumed to be at steady state conditions,
although some patients could have been at dosage titration.
Furthermore, the study was retrospective, and efficacy and
tolerability were not considered. The data were collected
before cannabinoids were introduced for treatment of MS
symptoms in Norway.
5. Conclusions
In this study we demonstrate a wide use of AEDs and
amitriptyline in a large population of patients withMS (31%).
Polypharmacy was widespread with 60% using additional
CNS-active drugs with a propensity to be involved in interac-
tions (5.4 drugs on average).One-third of the patientswere 60
years and above, which is a patient group that needs especially
careful pharmacological considerations. These results show
that the high prevalence of use of CNS-active drugs calls for
awareness of especially pharmacodynamic interactions and
possible excessive adverse effects in patients with MS.
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